Rheumatology
Previous Events
ACR Convergence 2021
UCLA's Division of Rheumatology was well represented at the 2021 ACR Convergence with 23 posters, 5 abstracts, 3 plenaries, 3 industry sessions, 3 community sessions, 1 review course, and 1 study group. Congratulations to the faculty and fellows who contribute to the presentations this year!
Posters:
- ANCA Positivity and ANCA Associated Vasculitis in Patients with Rheumatoid Arthritis
- Suppressed Paraoxonase-1 Activity and Elevated Oxylipins Associate with the Presence of Small Airways Disease in Patients with Rheumatoid Arthritis
- Economic and Healthcare Resource Use Burden of Systemic Sclerosis
- Safety and Tolerability of Nintedanib in Patients with Autoimmune Disease-Related Interstitial Lung Diseases: Pooled Data from the SENSCIS and INBUILD Trials
- Severity and Impact of Gastrointestinal Symptoms in Patients with SSc-ILD Treated with Nintedanib: Data from SENSCIS-ON
- Decreased HDL Levels and Antioxidant Function in Juvenile Dermatomyositis
- Suppression of HDL-associated Apolipoprotein A-I (apoA-I) Levels in Patients with Idiopathic Inflammatory Myopathies
- Lower HDL-associated Apolipoprotein A-I Levels Associate with Presence of Calcinosis in Adult Dermatomyositis
- Molecular Heterogeneity Between Different Classes of Lupus Nephritis as Revealed by Kidney Biopsy Proteomics
- Are Current Patient Reported Outcomes Instruments Optimized to Capture the Entire Patient Experience?
- Safety and Tolerability of IVIg (Octagam 10%) in Patients with Active Dermatomyositis. Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial
- Paraoxonase-1: Potential Novel Marker of Disease Extent and Activity in Systemic Sclerosis
- Autologous Hematopoietic Stem Cell (HSC) Transplantation for Systemic Sclerosis, North American Registry: Updated Outcomes and the Impact of CD34+ HSC Enrichment
- NLP-Based Clustering Methods Can Efficiently Categorize Scientific Abstracts for Medical Conferences
- “What Matters”: Patient and Clinician Perspectives in Psoriatic Arthritis Care
- Associations of Esophageal Dysmotility Patterns with Extra-intestinal Features in Patients with Systemic Sclerosis
- Outcomes of COVID-19 Illness in Systemic Autoinflammatory Diseases and Changes in Flares During the COVID-19 Pandemic: An International Survey
- Severity of Gastroesophageal Reflux, but Not the Use of Proton Pump Inhibitors, Is Associated with Radiographic Progression of Interstitial Lung Disease in Systemic Sclerosis
- Effect of Nintedanib in Patients with Systemic Sclerosis-associated Interstitial Lung Disease and Risk Factors for Rapid Decline in Forced Vital Capacity: Further Analyses of the SENSCIS Trial
- Peripheral Blood Cell Gene Expression Profiling Predicts Response to Mycophenolate in Systemic Sclerosis Related Interstitial Lung Disease
- Integrated Laboratory Abnormality Profiles of Upadacitinib with up to 4.5 Years of Exposure in Patients with Rheumatoid Arthritis Treated in a Phase 3 Clinical Trial
- Clinical Characteristics and Reliability of a Self-Reported Diagnosis of Large-Vessel Vasculitis
- Description of an Internet-Based Cohort with a Self-Reported Diagnosis of Polyarteritis Nodosa
Plenaries:
- Lupus Nephritis Mortality in the United States, 1999-2019: Profound Disparities by Race/Ethnicity and Place of Residence and a Recent Worsening Trend
- Risk Factors for Major Adverse Cardiovascular Events in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
- Genotype and Transfusion Dependence Predicts Mortality in VEXAS Syndrome, a Newly Described Disease with Overlap Inflammatory and Hematologic Features
Oral Abstract Sessions:
- Background Mycophenolate (MMF) Treatment Is Associated with Improved Outcomes in a Phase 3 Trial of Lenabasum in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
- Relationship Between Paraoxonase-1 Genotype, Activity, and Malignancies in Patients with RA Receiving Tofacitinib
- Trends in Adverse Pregnancy Outcomes Among Women with Systemic Sclerosis in the United States
- Clinical Heterogeneity of the VEXAS Syndrome: A Case Series
- The Risk of Venous Thromboembolic Events in Patients with RA Aged ≥ 50 Years with ≥ 1 Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
Review Courses:
Study Groups:
Industry Sessions:
- SAPHNELO™ (anifrolumab-fnia): The First-in Class Type 1 Interferon (IFN-1) Signaling Inhibitor
- Treatment Priorities in Systemic Lupus Erythematosus: Focus on Musculoskeletal Symptoms and Patient-Reported Outcomes
- Woman Leaders in Rheumatology: Leadership in a Virtual World